他汀类药物应成为心力衰竭治疗的一部分吗？

[Should statins be part of the treatment of heart failure?].

作者信息

Trochu J N

机构信息

Service de cardiologie, CHU de Nantes, boulevard Jacques-Monod, 44093 Nantes cedex, France.

出版信息

Ann Cardiol Angeiol (Paris). 2004 Jul;53(4):209-16. doi: 10.1016/j.ancard.2004.03.002.

DOI:10.1016/j.ancard.2004.03.002

PMID:15369317

Abstract

Beyond their lipid lowering properties HMG-CoA reductase inhibitors (statins) have numerous effects in the cardiovascular system. Commonly referred as "pleiotropic properties", these properties could justify the use of statins in the treatment of congestive heart failure. Excluding the beneficial effects of statins related to the prevention of coronary ischemic events, this review focuses on the emerging mechanisms which may explain the therapeutic potential of satins in heart failure, particularly their action on endothelial function, myocardial and renal energetic metabolism, inflammation, thrombosis, oxidative stress, ventricular remodeling and hypertrophy, and renal function.

摘要

除了其降脂特性外，HMG-CoA还原酶抑制剂（他汀类药物）在心血管系统中还有许多作用。这些特性通常被称为“多效性”，可能为他汀类药物用于治疗充血性心力衰竭提供依据。除了他汀类药物在预防冠状动脉缺血事件方面的有益作用外，本综述重点关注可能解释他汀类药物在心力衰竭中治疗潜力的新机制，特别是它们对内皮功能、心肌和肾脏能量代谢、炎症、血栓形成、氧化应激、心室重塑和肥大以及肾功能的作用。